Last reviewed 2026-04-22 · How we verify

PRECISION dosing Infliximab

Infliximab is a TNF-alpha inhibitor monoclonal antibody that binds and neutralizes tumor necrosis factor-alpha to reduce inflammatory responses.

Infliximab is a TNF-alpha inhibitor monoclonal antibody that binds and neutralizes tumor necrosis factor-alpha to reduce inflammatory responses. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.

At a glance

Mechanism of action

Infliximab is a chimeric monoclonal antibody that binds with high affinity to soluble and transmembrane TNF-alpha, preventing its interaction with TNF receptors on immune cells. This blocks the inflammatory cascade driven by TNF-alpha, reducing production of pro-inflammatory cytokines and adhesion molecules. PRECISION dosing refers to therapeutic drug monitoring and individualized dosing optimization to maintain therapeutic drug levels while minimizing toxicity.

Approved indications

• Rheumatoid arthritis
• Crohn's disease
• Ulcerative colitis
• Ankylosing spondylitis
• Psoriatic arthritis
• Psoriasis

Common side effects

• Infections (including tuberculosis, fungal, and opportunistic)
• Infusion reactions
• Headache
• Fatigue
• Abdominal pain
• Nausea
• Autoimmune phenomena (lupus-like syndrome)

Key clinical trials

• Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease (PHASE2, PHASE3)
• Precise Infliximab Exposure and Pharmacodynamic Control (PHASE2, PHASE3)
• Model-informed Dose De-escalation of Infliximab in Patients With Inflammatory Bowel Diseases (PHASE4)
• Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)
• Precision IFX: Using a Dashboard to Individualize Infliximab Dosage (NA)
• Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.